Synthetic antibody fragments targeting the HCV IRES RNA domain can inhibit viral translation, suggesting a potential therapeutic strategy against HCV.
No takes yet. Share an insight, caveat, or question.
Fabs enable HCV IRES structural studies; leaves open RNA-targeted antiviral development.
Koirala et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: